← Companies|Myokardia (BMS)
My

Myokardia (BMS)

S San Francisco CAFounded 2012150 employees
Private CapbiotechAcquiredCardiology
Platform: Mavacamten HCM
Market Cap
N/A
All Drugs
3
Clinical Trials
3
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
MYO-4326MYO-4326Phase 2/31mRNABETHER2EoE
LiraratamabMYO-7250Approved1NanobodyFcRnAuroraAiALSMDD
MYO-9608MYO-9608NDA/BLA1Gene EditingAPOC3PD-L1iEwing Sarcoma
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (2)
2026-03-11
MYO-9608 Conference
Ewing Sarcoma
Past
2028-04-15
MYO-9608 Ph3 Readout
Ewing Sarcoma
Ph3 Readout